The White House has unveiled a new trade policy targeting major pharmaceutical manufacturers, threatening to impose a 100% tariff on certain drugs unless companies agree to lower prices for American consumers and shift production to the United States.
Under the proposed measure, the steep tariff would apply to brand-name prescription medications and their active ingredients. Generic drugs, which account for the vast majority of prescriptions filled domestically, would be shielded from the levy for at least one year. Certain specialty medications, including those for rare diseases and veterinary use, would also be exempt if imported from nations with existing trade agreements or deemed critical for public health.
Officials outlined a pathway for companies to avoid the tariffs entirely by entering into formal pricing agreements with the administration and committing to domestic manufacturing. Firms that plan to increase U.S.-based production would face an initial 20% tariff, escalating to the full 100% rate over a four-year period.
To date, agreements have been reached with over a dozen major drugmakers, including industry giants Pfizer and Eli Lilly, granting them a three-year exemption. These companies, along with other large manufacturers, have a 120-day window to finalize deals before the tariff takes effect. Smaller firms have been allotted 180 days to negotiate.
The policy has drawn sharp criticism from industry representatives, particularly those representing mid-sized biotechnology companies. They argue the structure creates an uneven playing field, favoring large, multinational corporations with the resources and existing relationships to secure exemptions swiftly. Advocacy groups warn that smaller manufacturers, lacking diverse product lines, could struggle to absorb the sudden cost increases, potentially threatening drug supply and innovation.
The move intensifies the administration’s ongoing push to lower prescription drug costs, a persistent concern for U.S. households where prices significantly outpace those in other developed nations. It also arrives amid broader economic pressures, including rising consumer prices and energy costs, which have placed political focus on affordability issues.
This tariff announcement follows a series of recent economic proposals from the administration aimed at addressing the cost of living, including measures to curb corporate investment in residential housing and limit credit card interest rates. The focus on pharmaceutical pricing has been framed by supporters as a central component of this economic agenda.
